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Abstract
Background: Castleman's disease of the pancreas is a very rare condition that may resemble
more common disease entities as well as pancreatic cancer.
Case presentation: Here we report the case of a 58-year-old African American male with an
incidentally discovered lesion in the head of the pancreas. The specimen from his
pancreaticoduodectomy contained a protuberant, encapsulated mass, exhibiting microscopic
features most consistent with localized/unicentric Castleman's disease. These included florid
follicular hyperplasia with mantle/marginal zone hyperplasia along with focal progressive
transformation of germinal centers admixed with involuted germinal centers.
Conclusion: To date, eight cases of Castleman's disease associated with the pancreas have been
described in the world literature. We report the first case of unicentric disease situated within the
head of the pancreas. In addition, we discuss the diagnostic dilemma Castleman's disease may
present to the pancreatic surgeon and review current data on pathogenesis, treatment, and
outcome.
Background
Localized lymphoid hyperplasia of the pancreas is rarely
reported and is often indistinguishable from pancreatic
neoplasms both clinically or radiographically [1,2]. Cas-
tleman's disease (CD), a morphologically distinct form of
lymph node hyperplasia is very rare, and even more infre-
quent in the pancreas [3]. Currently, there are only eight
reported cases in the literature [3-10]. In our case, the
lesion within the head of the pancreas was presumed to be
a pancreatic carcinoma, and a classical pancreaticoduo-
denectomy (PD) was performed. Pathological examina-
tion instead revealed changes consistent with a localized
or unicentric hyaline-vascular (HV) variant of CD within
the head of the pancreas. In this communication, we
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review the diagnosis, pathogenesis, treatment, and out-
come for this rare clinical entity.
Case presentation
A 58-year-old African American male was seen in hepatol-
ogy clinic for a surveillance liver ultrasound following a
diagnosis of hepatitis C. The patient had experienced mild
intermittent upper abdominal pain consistent with a his-
tory of gastroesophageal reflux disease. He had no weight
loss, change in appetite or bowel habits, jaundice, or gen-
eral malaise. Past medical history included hyperlipi-
demia, peptic ulcer disease, and hepatitis C (antibody
positive, PCR negative). The patient's physical examina-
tion and laboratory studies were otherwise normal. A sur-
veillance abdominal ultrasound demonstrated a well
circumscribed mass measuring 3.4 × 2.9 cm within the
head of the pancreas. A computed tomography (CT scan)
further confirmed an enhancing mass involving the head
of the pancreas (Figure 1). No evidence of extra-pancreatic
disease was found on further evaluation. Although tumor-
associated antigen levels (CEA, CA 19-9, and CA-125)
were normal our differential diagnosis still included ade-
nocarcinoma of the pancreas. Endoscopic ultrasound
(EUS) guided needle biopsy was then performed but the
pathological findings were non-diagnostic. Our concern
for possible undetected malignancy remained and a diag-
nostic laparoscopy was performed followed by PD. The
patient recovered well following the procedure and was
discharged home on the 15th postoperative day. He con-
tinues to receive close outpatient surveillance without
additional treatment.
Pathologic findings
Within the PD specimen, a protuberant 4 × 3 × 3 cm cir-
cumferential mass at the superior border of the pancreatic
head was appreciated (Figure 2). The external surface of
the mass was tan/gray, firm, and smooth. Cut sections of
the mass also revealed a partially encapsulated large nod-
ule with tan/gray fleshy to firm parenchyma infiltrating
the pancreas at its distal portion. Surgical margins were
clear (Figure 3). Regional lymph nodes were identified
near the mass; microscopic examination revealed that all
were hyperplastic lymph nodes. The remaining surgical
margins were negative.
This lymphoid lesion within the pancreatic head showed
marked vascular proliferation and hyalinization of germi-
nal centers. Involuted germinal centers were surrounded
by concentric rings of small lymphocytes. i.e. "onion-skin-
ning" penetrated by hyalinized vessels (Figure 4). Moreo-
ver, the interfollicular zones were rich in plasma cells and
hyalinized vasculature. These features are consistent with
localized hyaline-vascular type CD. Distribution of T and
B cell markers (CD20, CD3, CD45) was normal and
markers indicative of lymphoid malignancies (i.e. CD30,
CD15, CD5, CD10, BCL-2) did not show evidence of such
entities. Furthermore, PCR analysis of paraffin-embedded
tissue revealed no clonal rearrangement of the immu-
noglobulin heavy chain or T-cell receptor gamma and
beta chain genes. MALT1 (18q21) clonal rearrangement
by FISH was negative. Together, these morphologic and
immunohistochemical findings are most consistent with
a diagnosis of CD.
A protuberant 4 × 3 × 2.8 cm, partially encapsulated, oval  mass within the superior border of the pancreatic head (P) Figure 2
A protuberant 4 × 3 × 2.8 cm, partially encapsulated, oval 
mass within the superior border of the pancreatic head (P). 
Arrows points to tan-gray fleshy firm cut surface of mass.
Computed tomography demonstrating enhancing mass pro- truding from the head of the pancreas Figure 1
Computed tomography demonstrating enhancing mass pro-
truding from the head of the pancreas. White arrow points 
to Castleman's disease in pancreas.World Journal of Surgical Oncology 2007, 5:133 http://www.wjso.com/content/5/1/133
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Discussion
Historically, CD, also known as angiofollicular lymph
node hyperplasia, remains a rare and poorly understood
disease characterized by massive growth of lymphoid tis-
sue. CD was first described as a pathological entity in
1954 and later defined by Castleman et al., in 1956 [11].
A variety of terms have been used to describe this disorder,
including giant lymph node hyperplasia, lymph node
hamartoma, follicular lymophoreticuloma, benign giant
lymphoma, angiomatous lymphoid hamartoma, and
angiofollicular mediastinal lymph node hyperplasia.
Flendrig and Schillings [12] described two basic his-
topathological subtypes and one mixed variant which Kel-
ler et al. [13] later designated HV, plasma cell (PC), and
hyaline-vascular plasma cell "mixed" types (HV-PC). Cat-
egorization of CD into clinically relevant subtypes was
proposed by McCarty et al. [14] and Gaba et al. [15] into
unicentric and multicentric variants, respectively. In gen-
eral, HV-CD is commonly associated with a localized -
asymptomatic mass (76–91%) [15,16], while PC-CD is
usually multicentric and symptomatic in 50% of patients.
Unicentric and multicentric CD differ in their clinical
presentation and distribution of adenopathy. In a series
from Memorial Sloan-Kettering Cancer Center (MSKCC)
[16], patients with unicentric CD were frequently discov-
ered incidentally with symptoms mostly arising from
mass compression. Masses found in unicentric disease
were usually centrally located in the abdomen and pelvis
(54%) and mediastinum (31%), whereby systemic symp-
toms, central and peripheral adenopathy, organomegaly,
and associated abnormal laboratory values (elevated
erythrocyte sedimentation rates [ESR], interleukin-6 [IL-
6], anemia and polyclonal gammaglobulinemia) were
predominant in the multicentric variant.
Our current understanding of the pathogenesis of CD
points to reactive follicular hyperplasia in response to an
unknown antigenic stimulus [17]. In the current report,
the role of HCV infection (positive serology for anti-HCV)
in the pathogenesis of HV-CD is possible. This view has
been shared by others. Multicentric PC-CD has been pre-
viously reported to be associated with concurrent HCV
infection in a child with Klinefelter's syndrome and non-
regulated antibody production mimicking systemic lupus
erythematosus stabilized by interferon-alpha therapy sug-
gesting an association with HCV [18]. Likewise, a report
associating reactive lymphoid hyperplasia representing a
pseudo-lymphoma of the liver was detailed in a patient
with chronic hepatitis C [19]. Moreover, the potential role
of HCV infection in an antigen-driven lymphoprolifera-
tive model for the pathogenesis of unrelated lymphopro-
liferative disease entities including non-Hodgkin's
lymphoma, marginal zone B-cell lymphoma, or extran-
odal marginal zone B-cell lymphoma of mucosa-associ-
ated lymphoid tissue (MALT) further supports this
hypothesis. Nevertheless, the association of concurrent
HCV infection and HV-CD requires further investigation.
In addition, other etiologies including chronic low grade
inflammation [11], harmartomatous process [20,21],
immunodeficiency [22-24], and autoimmunity [25] have
all been proposed as possible pathogenic mechanisms.
Epstein-Barr virus, Toxoplasma, and Mycobacterium tuber-
culosis  also have been linked to this disorder [13,25].
Interestingly, lymph nodes from various animal models
and patients with CD implicate IL-6 as a causative agent
for the commonly observed systemic manifestations
[20,26-29].
The initial challenge in CD remains in establishing the
diagnosis. Considerable imprecision exists in distinguish-
ing CD from other lymphoid and non-lymphoprolifera-
tive disorders that it may resemble clinically and
pathologically [30]. Therefore, in the appropriate clinical
setting, the diagnosis of CD must be considered, after
investigating and excluding more common causes of lym-
phadenopathy or associated neoplastic processes. Intra-
operatively, distinguishing CD involving the head of the
pancreas from pancreatic carcinoma may be problematic
and strong suspicion of pancreatic malignancy as in our
case may prompt traditional surgical removal. Possible
clues for the pancreatic surgeon may include evidence of
an encapsulated pancreatic mass that is well-circum-
scribed, and smooth; an uncommon finding for pancre-
atic adenocarcinoma. Indeed, the diagnosis ultimately
rests on precise pathologic investigation.
Castleman's disease (CD) infiltrating normal pancreatic tissue  (P) (hematoxylin-eosin, original magnification × 100) Figure 3
Castleman's disease (CD) infiltrating normal pancreatic tissue 
(P) (hematoxylin-eosin, original magnification × 100). Black 
arrow demonstrates infiltration of CD into normal pancreas.World Journal of Surgical Oncology 2007, 5:133 http://www.wjso.com/content/5/1/133
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Unicentric CD is largely the HV- type. HV-CD typically
occurs as an isolated lymph node mass or regional aden-
opathy. These patients are frequently asymptomatic. From
a histopathologic standpoint, "lollipop" follicles; germi-
nal centers surrounded by circumferentially arranged lay-
ers ("onion skin") of small lymphocytes interconnected
by a prominent vascular stroma are characteristic patho-
logical findings. In this report, our patient had all the clas-
sical features of unicentric HV-CD. Conversely, the PC-CD
subtype demonstrates continuous sheets of dense plasma
cells and a less vascular interfollicular stroma surrounding
the germinal centers [13].
Unicentric CD specifically involving the pancreas is
extremely rare, with only eight cases described worldwide
[3-10] (Table 1). The majority of these cases were of the
HV-subtype and discovered incidentally. The PC-subtype
typically presents with systemic symptoms. In those cases
with patient follow-up it appears that resection may offer
short-term control of disease with resolution of associated
symptomatology.
Additional studies have further clarified the natural his-
tory following resection. From a consensus standpoint,
surgical resection is the mainstay of treatment for unicen-
tric CD with most reports describing complete resection as
being curative. In a recent report from MSKCC [16], com-
plete resection of unicentric disease was curative for all
patients regardless of histologic subtype. Likewise, Keller
et al. [13] retrospectively examined 61 patients with uni-
centric disease who were treated with surgery over a 20
year period. Their study demonstrated that for patients
with unicentric HV-CD, complete resection offered the
best chance for cure. In certain cases, if complete resection
is not possible, partial resection or observation with long
term follow-up may be useful. As reported, radiographic
examination (CT or MRI) along with arteriography and
embolization has been used to facilitate surgical excision
and minimize intraopertative bleeding, which can be pro-
fuse [31-34].
A limited number of reports address the response of CD
to radiotherapy (2700–4500 cGy) administered to
involved sites which has resulted in remission of disease
in isolated cases [28,35-42], but failed in others
[13,15,43]. Keller et al. [13], reported on four patients
with unicentric-HV disease who were treated with 1800–
4300 cGy with no response. Notably, a complete response
of the unicentric-HV variant was reported by Sethi et al.
[40], in a patient with systemic symptoms treated with
4000 cGy. However, irradiation was noted to produce a
range of favorable responses in all patients of PC or mixed
histology [35,36,38,39,42]. These results point to a better
Table 1: Summary of patients with unicentric Castleman's disease involving the pancreas
Author Site Symptoms Subtype Treatment Outcome
Goetze3 Tail of Pancreas No HV-CD DP NED (2 Yrs)
Erkan4 Peripancreatic Abdominal pain* PC-CD Enucleation NED (1 yr)
Baikovas5 Peripancreatic No HV-CD Excision NA
Lepke6 Body and Tail No HV-CD STP NA
Corbisier7 Peripancreatic Abdominal pain HV-CD Excision NA
LeVan8 Tail of Pancreas Back pain HV-CD DP NA
LeBorgne9 Uncinate Process Systemic PC-CD PD NED+ (11 mos)
Brossard10 Tail of Pancreas Systemic PC-CD DP +
Current Report Head of Pancreas No HV-CD PD NED (1 yr)
HV-CD: hyaline vascular Castleman's disease; PC-CD: plasma cell Castleman's disease;
* Elevated erythrocyte sedimentation rate, C-reactive protein, and hypergammaglobulinemia; DP: distal pancreatectomy; STP; subtotal 
pancreatectomy;
PD: pancreaticoduodenectomy; + resolution of systemic symptoms;
NED: No evidence of disease; NA: Not available
Hyaline-vascular-CD Figure 4
Hyaline-vascular-CD. Involuting germinal center surrounded 
by concentric rings of small lymphocytes penetrated by hyali-
nized vessel (hematoxylin-eosin, original magnification × 
400).World Journal of Surgical Oncology 2007, 5:133 http://www.wjso.com/content/5/1/133
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response when radiotherapy is administered at an earlier,
more active stage of disease (PC and mixed- HV-PC uni-
centric subtypes), rather than with the later, less metabol-
ically active HV-subtype.
Subsequently, close follow-up and periodic surveillance
are necessary to detect concurrent or ensuing malignant
lesions (lymphoproliferative disease and vascular neo-
plasms) [44,45] associated with CD. Notably, local recur-
rence has been reported as long as 11 years after complete
resection.
In contrast, no effective therapy has been established for
multicentric disease which is widely viewed as a systemic
disease. Among very rare cases, surgery may play a limited
role for cases of palliation of systemic symptoms. Steroids,
single-agents, or combination chemotherapy, plus immu-
notherapy are currently being employed with results rang-
ing from rare cases of complete remission, sustained
manifestations of disease, to aggressive disease biology
with rapidly fatal outcomes [43,46,47]. The worst progno-
sis is for patients with multicentric disease, PC-subtype,
and clinical signs of neuropathy. This group appears
refractory to all therapy [46]. Long term survival may be
possible in multicentric patients harboring the HV- sub-
type.
In this report, our patient underwent a PD for a presumed
pancreatic cancer. In most cases, surgeons who treat pan-
creatic cancer will usually proceed to surgery without
biopsy if the evidence of malignancy is strong. In this case,
the initial biopsy did not demonstrate cancer. However, a
study that is negative for tumor should not always be
interpreted as meaning that no tumor exists. In this
instance, a curable form of CD was resected. Due to the
rarity of this disease, a diagnosis of CD will usually occur
well after pathologic exclusion of other more common
disease entities.
Conclusion
CD is a poorly understood disease that creates both a diag-
nostic and therapeutic dilemma for surgeons. Complete
surgical resection of unicentric disease at the time of pres-
entation is likely to afford the best chance for cure. Radia-
tion therapy has been used with varied success in patients
who are poor surgical candidates or in those with unre-
sectable lesions. Long term follow-up is necessary with
regard to malignant sequelae. The role of surgery in mul-
ticentric disease is limited and should not be considered a
realistic treatment option. Systemic therapy in the form of
steroids, single or multiple drug chemotherapies have all
been used with varied success. However, there is no evi-
dence for one approach being more consistently effective.
A better understanding of the pathogenesis, natural his-
tory, and ultimately diagnosis of this disorder may lead to
improvement over the current modalities available for
treatment.
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